Results 231 to 240 of about 4,478,342 (326)

Impact of a low‐carbohydrate diet on cardiometabolic parameters in individuals with and without diabetes: An 8‐year longitudinal study within the ELSA‐Brasil cohort

Nutrition in Clinical Practice, EarlyView.
Abstract Background Low‐carbohydrate diets (LCDs) are widely adopted for metabolic management, but their long‐term cardiometabolic effects in diverse populations remain unclear. We aimed to evaluate the association between self‐selected moderate LCD adherence and cardiometabolic parameters in individuals with and without diabetes.
Leticia Batista de Azevedo, Haysla Xavier Martins, Oscar Geovanny Enriquez‐Martinez, Maria del Carmen Bisi Molina   +3 more
wiley   +1 more source

Association between the modified cardiometabolic index and asthma among participants in the United States: A cross-sectional NHANES analysis. [PDF]

Medicine (Baltimore)
Fang Y, Wang M, Liu Y, Lin Z, Wang X, Zhang Q.   +5 more
europepmc   +1 more source

Identifying DASH Adherence Patterns and Their Association With Dietary Behaviors Among Adults With Hypertension

Research in Nursing &Health, EarlyView.
ABSTRACT The Dietary Approaches to Stop Hypertension (DASH) diet is effective in lowering blood pressure yet adherence to DASH remains low. Intuitive eating, a behavior that emphasizes responsiveness to hunger and satiety cues, may influence DASH adherence but has not been well studied among adults with hypertension.
Youran Lee, Melissa C. Kay, Anushka Palipana, Sandy Askew, Miriam B. Berger, Hailey N. Miller, Gary G. Bennett, Qing Yang   +7 more
wiley   +1 more source

Association between modified cardiometabolic index and cardiometabolic multimorbidity in middle-aged and older adults: evidence from two nationwide cohort studies. [PDF]

Sci Rep
Chen S, Lv T, Zhou J.
europepmc   +1 more source

Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis

Obesity, EarlyView.
ABSTRACT Objective This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381).
Inês Rego de Figueiredo, Filipa Sofia Simas, Angela Ghiletchi, João Oliveira Torres, José Silva‐Nunes   +4 more
wiley   +1 more source

The combined effects of cardiometabolic index and high sensitivity C-reactive protein on cardiometabolic multimorbidity risk: a prospective analysis based on CHARLS. [PDF]

Lipids Health Dis
Hua H, Zhao J, Zhou Z, He S, Mei S, Fei X, Xu X, Yan X, Li L, Zhu J, Wu Q, Li W.   +11 more
europepmc   +1 more source

Beyond BMI: The Impact of the New Lancet Commission Diagnostic Criteria on Prevalence of Obesity in the United States

Obesity, EarlyView.
ABSTRACT Objective This study compared population characteristics and overall US prevalence of obesity over time using the BMI criteria and the 2025 Lancet Commission criteria (i.e., the Excess Adiposity criteria). Methods We analyzed data from 58,053 adults aged ≥ 20 years in the National Health and Nutrition Examination Survey from 1999 to 2023.
Jennifer H. Hwang, Neda Laiteerapong
wiley   +1 more source

Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999-2018. [PDF]

Cardiovasc Diabetol
Yu C, Qiu C, Zhang Q, Wang W, Liu S, Jin Z.   +5 more
europepmc   +1 more source

Retatrutide Shows Multiple Metabolic Benefits in Diet‐Induced Obese MASH Mouse and Hamster Models

Obesity, EarlyView.
ABSTRACT Objective/Methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP‐1 receptor agonist retatrutide in diet‐induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
François Briand, Camille Le Cudennec, Estelle Grasset, Natalia Breyner, Claire Bigot, Pierre Dillard, Thierry Sulpice   +6 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source